查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606663

Darbepoetin汀阿爾法市場：按交付方式、應用和最終用戶分類 - 全球預測 2025-2030

Darbepoetin Alfa Market by Mode of Delivery (Intravenous, Subcutaneous), Application (Cancer, Chronic Kidney Disease), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年Darbepoetin汀阿爾法市場估值為7,815萬美元，預計2024年將達8,219萬美元，複合年成長率為5.31%，預計2030年將達1,1227萬美元。

Darbepoetin alfa 是一種合成的紅血球生成刺激因子 (ESA)，主要用於治療與慢性腎臟病和化療相關的貧血。它的需求源於其緩解貧血症狀、改善生活品質和減少輸血需求的能力。Darbepoetin法的用途遍及醫療機構，最終用途集中在醫院藥房和管理貧血患者的門診中心。推動市場的主要因素包括慢性病（包括慢性腎臟病和癌症）盛行率的上升，這增加了貧血的發生率。此外，技術進步和針對生物相似藥的持續研究努力正在推動市場的成長，其中成本效益是一個關鍵因素。該市場的最新機會在於擴大對開拓的貧血病症的應用，並透過策略夥伴關係和提高認知的教育舉措進一步提高新興市場的接受度。然而，嚴格的監管監督、高昂的治療成本以及與 ESA 相關的血栓栓塞風險等安全問題構成了重大限制。此外，來自替代性貧血治療（包括非 ESA 藥物）的激烈競爭對市場成長構成了挑戰。為了促進創新，研究需要集中在提高緩釋性和聯合治療的功效和安全性。探索基因療法在治療與腫瘤學和腎臟病學相關的貧血中的應用可能會開闢新的途徑。此外，快速成長的生物相似藥領域對於尋求降低成本和提高可及性的公司來說是一個利潤豐厚的領域。隨著市場在國際上不斷成長，了解當地的監管環境至關重要。總體而言，Darbepoetin汀阿爾法市場具有巨大的成長潛力，但與監管指導保持一致並透過嚴格的臨床試驗解決安全問題對於持續成功和市場擴張至關重要。

主要市場統計
基準年[2023] 7815萬美元
預計年份 [2024] 8219萬美元
預測年份 [2030] 11227萬美元
複合年成長率（%） 5.31%

市場動態：快速發展的Darbepoetin法市場的關鍵市場洞察

Darbepoetin汀阿爾法市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球慢性病和癌症盛行率不斷上升
    • 醫改進展及保險政策支持
  • 市場限制因素
    • 產品召回的潛在風險
  • 市場機會
    • 科技創新為Darbepoetin法帶來新的治療適應症
    • 生物製藥製造技術進展
  • 市場挑戰
    • 替代治療的可用性

波特的五力：駕馭Darbepoetin法市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解Darbepoetin汀阿爾法市場的外部影響

外部宏觀環境因素在塑造Darbepoetin汀阿爾法市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解Darbepoetin汀阿爾法市場的競爭狀況

對Darbepoetin汀阿爾法市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣Darbepoetin Alfa 市場供應商的績效評估

FPNV定位矩陣是評估Darbepoetin Alfa市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製Darbepoetin汀阿爾法市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，Darbepoetin汀阿爾法市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地慢性病和癌症的發生率正在增加
      • 擴大醫療改革和支持性保險政策
    • 抑制因素
      • 產品召回的潛在風險
    • 機會
      • 為Darbepoetin法帶來新治療適應症的創新
      • 生物藥製造技術進展
    • 任務
      • 替代治療方法的可用性
  • 市場區隔分析
    • 給藥方法：由於皮下注射Darbepoetin法可有效治療與慢性腎臟病相關的貧血，因此其需求不斷增加。
    • 用途：增加Darbepoetin法在慢性腎臟病的使用，以刺激紅血球生成並治療貧血
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章Darbepoetin法市場運輸方式

  • 靜脈
  • 皮下的

第7章Darbepoetin法市場：依應用分類

  • 癌症
  • 慢性腎臟病

第 8 章Darbepoetin法市場：按最終用戶

  • 居家護理
  • 醫院
  • 專科診所

第9章Darbepoetin法北美、南美市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 達貝Darbepoetin太地區市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章Darbepoetin法歐洲、中東和非洲市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准Lebrozil 作為骨髓發育不良症候群的一線貧血治療藥物
  • 戰略分析和建議

公司名單

  • Amgen Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Johnson & Johnson Services, Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Novartis
Product Code: MRR-237D3592FD11

The Darbepoetin Alfa Market was valued at USD 78.15 million in 2023, expected to reach USD 82.19 million in 2024, and is projected to grow at a CAGR of 5.31%, to USD 112.27 million by 2030.

Darbepoetin Alfa, a synthetic erythropoiesis-stimulating agent (ESA), is used for treating anemia primarily associated with chronic kidney disease and chemotherapy. Its necessity stems from its ability to alleviate anemia symptoms, improve quality of life, and reduce the need for blood transfusions. The application of Darbepoetin Alfa spans healthcare facilities, with its end-use highly concentrated in hospital pharmacies and outpatient centers that manage anemic patients. A major driving factor in the market includes the rising prevalence of chronic diseases, inclusive of CKD and cancer, that elevate anemia incidence. Furthermore, technological advancements and ongoing research efforts focused on biosimilars accentuate market growth, where cost-effectiveness is a significant factor. The latest opportunities within the market lie in expanding its application for unexplored anemic conditions and furthering its acceptance in emerging markets through strategic partnerships and educational initiatives to raise awareness. However, stringent regulatory scrutiny, high treatment costs, and safety concerns, such as the thromboembolic risk associated with ESAs, pose considerable limitations. Furthermore, market growth is challenged by the rising competition from alternative anemia treatments, including non-ESA agents. To foster innovation, research could focus on improving the efficacy and safety profile of Darbepoetin Alfa through extended-release formulations or combination therapies. Exploring gene therapy applications within oncology or nephrology-related anemia treatment may open new avenues. Additionally, the burgeoning biosimilars space presents a lucrative area for businesses to reduce costs and increase accessibility. Understanding regional regulatory landscapes will be crucial as the market continues to grow internationally. Overall, while the Darbepoetin Alfa market exhibits significant growth potential, aligning with regulatory guidance and addressing safety concerns through rigorous clinical trials will be imperative for sustained success and market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 78.15 million
Estimated Year [2024] USD 82.19 million
Forecast Year [2030] USD 112.27 million
CAGR (%) 5.31%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Darbepoetin Alfa Market

The Darbepoetin Alfa Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic diseases and cancer worldwide
    • Growing healthcare reforms and supportive insurance policies
  • Market Restraints
    • Potential risk of product recall
  • Market Opportunities
    • Innovations leading to new therapeutic indications for darbepoetin alfa
    • Advancements in biological drug production technologies
  • Market Challenges
    • Availability of alternative treatments

Porter's Five Forces: A Strategic Tool for Navigating the Darbepoetin Alfa Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Darbepoetin Alfa Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Darbepoetin Alfa Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Darbepoetin Alfa Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Darbepoetin Alfa Market

A detailed market share analysis in the Darbepoetin Alfa Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Darbepoetin Alfa Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Darbepoetin Alfa Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Darbepoetin Alfa Market

A strategic analysis of the Darbepoetin Alfa Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Darbepoetin Alfa Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Dr. Reddy's Laboratories Ltd., Johnson & Johnson Services, Inc., Kyowa Hakko Kirin Co., Ltd., and Novartis.

Market Segmentation & Coverage

This research report categorizes the Darbepoetin Alfa Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Mode of Delivery, market is studied across Intravenous and Subcutaneous.
  • Based on Application, market is studied across Cancer and Chronic Kidney Disease.
  • Based on End User, market is studied across Home Care, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases and cancer worldwide
      • 5.1.1.2. Growing healthcare reforms and supportive insurance policies
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of product recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations leading to new therapeutic indications for darbepoetin alfa
      • 5.1.3.2. Advancements in biological drug production technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Mode of Delivery: Increasing demand for darbepoetin alfa administered subcutaneously due to its effectiveness in treating anemia associated with chronic kidney disease
    • 5.2.2. Application: Growing use of darbepoetin alfa in chronic kidney disease to treat anemia by stimulating the production of red blood cells
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Darbepoetin Alfa Market, by Mode of Delivery

  • 6.1. Introduction
  • 6.2. Intravenous
  • 6.3. Subcutaneous

7. Darbepoetin Alfa Market, by Application

  • 7.1. Introduction
  • 7.2. Cancer
  • 7.3. Chronic Kidney Disease

8. Darbepoetin Alfa Market, by End User

  • 8.1. Introduction
  • 8.2. Home Care
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Darbepoetin Alfa Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Darbepoetin Alfa Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Darbepoetin Alfa Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Approved Reblozyl as First-Line Anemia Treatment for Myelodysplastic Syndromes
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Dr. Reddy's Laboratories Ltd.
  • 3. Johnson & Johnson Services, Inc.
  • 4. Kyowa Hakko Kirin Co., Ltd.
  • 5. Novartis

LIST OF FIGURES

  • FIGURE 1. DARBEPOETIN ALFA MARKET RESEARCH PROCESS
  • FIGURE 2. DARBEPOETIN ALFA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DARBEPOETIN ALFA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DARBEPOETIN ALFA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DARBEPOETIN ALFA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DARBEPOETIN ALFA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DARBEPOETIN ALFA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DARBEPOETIN ALFA MARKET DYNAMICS
  • TABLE 7. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. DARBEPOETIN ALFA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. DARBEPOETIN ALFA MARKET, FPNV POSITIONING MATRIX, 2023